Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work on Colonizing Biotherapies

Zarrinpar lab discovers that engineering native bacteria for therapeutic applications facilitates engraftment and long-term treatment


Endure Organic

San Diego, Aug. 15, 2022 (GLOBE NEWSWIRE) —


Endure BiotherapeuticsInc. announcement Publication of Founder Pioneering work on colonizing biotherapies

Zarrinpar Llaboratory discoveries eat native bacteria engineering for therapeutic applications facilitates long term transplant and treatment

SAN DIEGO – August 152022 Endure Biotherapeutics, Inc. (Endure Bio®), a leader in microbial therapies designed to treat gastrointestinal and metabolic disorders, announced the publication of the seminal article from the laboratory of Amir Zarrinpar, MD , PhD, assistant professor of medicine at UC San Diego, founder and chief medical officer of Endure Bio. The article by Dr. Zarrinpar and colleagues, “Intestinal Transgene Delivery with Native E. coli Chassis enables persistent physiological changes” was published in the journal Cell August 14.

Endure Bio, the exclusive licensee of this UCSD technology, was founded to pursue the development of live graftable biotherapeutics to not only treat but also potentially cure patients with chronic diseases using Dr. Zarrinpar’s breakthrough technology incorporating engineered native bacteria (IN B). Unlike other companies that pursue the development of therapeutic products based on laboratory bacterial strains, Endure Bio uses native bacteria isolated from human and other mammalian hosts which are then modified to treat specific diseases. As described in the Cell article, Dr. Zarrinpar discovered that bacteria from the mammalian host, engineered to produce a beneficial transgene and reintroduced into a host of the same species, can survive and engraft, resulting in a sustained physiological change in the host and an improvement in chronic diseases.

“From a business perspective, this means we can use human-derived microbes to produce the therapies they need, leading to the development of a wide variety of live biotherapeutic products,” said Dr. Zarrinpar. “Understanding how to construct engineered bacteria that can colonize and consistently express an altered gene will be essential for live therapies to work for human disease. Studies have shown that bacteria that are already members of the gut microbiome can achieve long-term colonization. We now show that these bacteria can be used to introduce therapeutic functions and ameliorate disease. Therefore, ENBs are key to treating a range of chronic and recalcitrant diseases, not only limited to digestive disorders such as inflammatory bowel disease, but also metabolic diseases such as type 2 diabetes and even rare genetics. It is incredibly rewarding to see the accomplishments of our academic team and see how they could translate into a new class of biotherapies.

Endure Bio focuses on a number of therapeutic areas, including rare diseases such as phenylketonuria (PKU), a genetic condition affecting the body’s ability to process dietary protein, as well as more common disorders such as inflammation of the intestine.

About Zarrinpar Laboratory

The Zarrinpar lab is interested in the intersection of circadian biology, gut physiology, and the gut microbiome and how the three interact to cause obesity, diabetes, steatohepatitis, and other gut-mediated diseases . We are interested in the reciprocal interaction between the gut and its contents and how they regulate the expression, absorption, nutrient sensing and signaling of normal gut genes. By studying these interactions, we hope to find new ways to treat difficult diseases. The Zarrinpar lab has received funding from the National Heart, Lung, Blood Institute, National Institute of Diabetes and Digestive and Kidney, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, and National Institute of Child Health and Human Development, as well as the American Federation for Research in Aging and the National Phenylketonuria Alliance for research related to modified native bacteria. For more information, please visit http://zarrinparlab.org/ or follow the lab on Twitter @Zarrinparlab

About Endure Biotherapeuticsa Cool Company 2022

Endure Biotherapeutics® leads the discovery, development and commercialization of engraftable live biotherapeutics for the treatment of genetic and chronic diseases. Unlike other gut-focused microbiome companies, Endure Bio’s powerful therapeutic platform facilitates in vitro engineering bacterial strains that remain resident in the gastrointestinal tract after oral administration. Modified native bacteria (ENB) have the potential to not only treat but, because they engraft and colonize the gut, to cure patients with chronic diseases. Endure Bio’s fundamental microbiome therapeutic platform is based on the pioneering work of Amir Zarrinpar, MD, PhD, assistant professor of medicine at UC San Diego School of Medicine. For more information, please visit http://www.endurebio.com/. Twitter: @EndureBio




CONTACT: Mark S. Wilson [email protected] +1.858.752.9003

Comments are closed.